ADQ, an Abu Dhabi-based investment and holding company, has launched a paper that explores the opportunities and investments that will position the UAE to become a leading regional pharma manufacturing hub.
The ADQ FWD paper focuses on how the UAE can reach its full potential to increase regional pharmaceutical capacity and create seamless access to affordable medications and innovative treatments.
The publication follows ADQ’s partnership with several companies within Pure Health to create the largest healthcare provider in the UAE.
As part of the agreement, Abu Dhabi Health Services Company (SEHA), and The National Health Insurance Company (Daman) will merge into Pure Health.
Additionally, Tamouh Healthcare, Yas Clinic Group and Abu Dhabi Stem Cell Centre will also become a part of Pure Health, which already has a diversified services portfolio of hospital management, laboratory services, medical supplies and healthcare informatics.
It identifies six cornerstones of success to enable the UAE to capture pharma growth opportunities in the region.
These include establishing more robust cooperation between the public and private sectors and academia, public health programs and research and establishing a stronger life sciences R&D ecosystem for the production of novel and innovative medicines and vaccines.
The paper also calls for the development of more UAE-based biotech and life sciences parks and increasing investment into industrial areas that promote self-sufficient production of basic and consumer commodities.
According to ADQ, bilateral relationships need to be further leveraged to foster investment in clinical research that addresses healthcare needs while diverse skillsets in various healthcare disciplines need to be nurtured to develop homegrown talent and expertise.
Fahad Al Qassim, executive director, Healthcare & Life Sciences, ADQ, said: “We are deploying capital to build a pharma hub that further strengthens the UAE’s regional leadership in the industry.
“As we invest in expanding capabilities, deepening the talent pool and increasing manufacturing drugs locally, we are helping to redefine the regional pharma landscape.
“This paper emphasises the importance we place on ensuring that our community has access to essential pharmaceuticals for the long-term, which is one of the key aspects of our commitment to being a sustainable investor.”
ADQ FWD is a platform that brings together industry experts, government, and advocacy leaders to discuss matters of economic and strategic importance.
Last September, ADQ agreed to wholly acquire Swiss-based Acino, a pharmaceutical provider focused on growth-leading markets across the Middle East, Africa, Latin America, Russia, Ukraine and the CIS region.
Earlier last year, ADQ agreed to acquire Pharmax Pharmaceuticals, a UAE-based company which manufactures and markets affordable, branded generic medication while also investing in a minority stake in Biocon Biologics Limited that specialises in developing, manufacturing and marketing high-quality, affordable biosimilars across global markets.
Follow us on
